var docs;if (!docs) docs =[]; docs["69"]={"6904":"<p><b>Title</b> Glimepiride / Colesevelam</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Colesevelam may decrease the serum concentration of Glimepiride. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer glimepiride at least 4 hours prior to colesevelam.</p> \n<p><b>Discussion</b> In a clinical study summarized in colesevelam prescribing information, simultaneous administration of colesevelam (3.75 g) with glimepiride (4 mg) decreased glimepiride maximum concentration (Cmax) and AUC by 8% and 18%, respectively.<sup>1,2</sup> Administration of glimepiride 4 hours prior to colesevelam decreased glimepiride Cmax and AUC by 3% and 6%, respectively. Colesevelam prescribing information states that glimepiride should be administered at least 4 hours prior to colesevelam.<sup>1</sup> The suspected mechanism of this interaction is colesevelam binding to glimepiride in the gastrointestinal tract, thereby decreasing glimepiride absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc., 6/2012.</p>\n<p>2. He L, Wickremasingha P, Lee J, et al. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil. <i>J Clin Pharmacol</i>. 2013 Sep 10. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24019110\">[PubMed 24019110]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6905":"<p><b>Title</b> GlipiZIDE / Colesevelam</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Colesevelam may decrease the serum concentration of GlipiZIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer glipizide at least 4 hours prior to colesevelam.</p> \n<p><b>Discussion</b> In a clinical study summarized in colesevelam prescribing information, simultaneous administration of colesevelam (3.75 g) with glipizide (20 mg) decreased glipizide maximum concentration (Cmax) and AUC by 13% and 12%, respectively.<sup>1,2</sup> Administration of glipizide 4 hours prior to colesevelam decreased glipizide AUC by 4% and did not alter Cmax. Colesevelam prescribing information states that glipizide should be administered at least 4 hours prior to colesevelam.<sup>1</sup> The suspected mechanism of this interaction is colesevelam binding to glipizide in the gastrointestinal tract, thereby decreasing glipizide absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc., 6/2012.</p>\n<p>2. He L, Wickremasingha P, Lee J, et al. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil. <i>J Clin Pharmacol</i>. 2013 Sep 10. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24019110\">[PubMed 24019110]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6906":"<p><b>Title</b> Olmesartan / Colesevelam</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Colesevelam may decrease the serum concentration of Olmesartan. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Administer olmesartan at least 4 hours prior to colesevelam.</p> \n<p><b>Discussion</b> In a clinical study summarized in colesevelam prescribing information, simultaneous administration of colesevelam (3.75 g) with olmesartan medoxomil (40 mg) decreased olmesartan maximum concentration (Cmax) and AUC by 28% and 39%, respectively.<sup>1,2</sup> Administration of olmesartan medoxomil 4 hours prior to colesevelam decreased olmesartan Cmax and AUC by 4% and 15%, respectively. Colesevelam prescribing information states that olmesartan should be administered at least 4 hours prior to colesevelam.<sup>1</sup> The suspected mechanism of this interaction is colesevelam binding to olmesartan in the gastrointestinal tract, thereby decreasing olmesartan absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc., 6/2012.</p>\n<p>2. He L, Wickremasingha P, Lee J, et al. The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil. <i>J Clin Pharmacol</i>. 2013 Sep 10. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24019110\">[PubMed 24019110]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6907":"<p><b>Title</b> Mirtazapine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Mirtazapine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving mirtazapine should avoid use of alcohol, due to the potential for additive cognitive and motor impairment.</p> \n<p><b>Discussion</b> In a study of 6 healthy volunteers, the concomitant administration of alcohol (60 g equivalent) minimally influenced mirtazapine (15 mg) plasma concentrations but enhanced cognitive and motor impairment in an additive manner.<sup>1</sup> Mirtazapine prescribing information recommends that patients be advised to avoid alcohol during mirtazapine treatment.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Remeron (mirtazapine). Whitehouse Station, NJ: Merck &amp; Co., Inc., 12/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6908":"<p><b>Title</b> Mirtazapine / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced cognitive and motor impairment when mirtazapine is used in combination with a CNS depressant. Advise patients to avoid any unprescribed, illicit, or recreational use of other CNS depressants.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> In a study of 12 healthy volunteers, the concomitant administration of diazepam (15 mg) minimally influenced mirtazapine (15 mg) plasma concentrations but enhanced cognitive and motor impairment in an additive manner.<sup>1</sup> Mirtazapine prescribing information recommends that patients be advised to avoid diazepam and related drugs during mirtazapine treatment.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Remeron (mirtazapine). Whitehouse Station, NJ: Merck &amp; Co., Inc., 12/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6909":"<p><b>Title</b> Mirtazapine / Tryptophan</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tryptophan may enhance the serotonergic effect of Mirtazapine. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of tryptophan and mirtazapine in combination.</p> \n<p><b>Discussion</b> Mirtazapine prescribing information states that concomitant use of mirtazapine with serotonin precursors such as tryptophan is not recommended.<sup>1</sup> Tryptophan and mirtazapine are both expected to enhance serotonergic neurotransmission, so their combination could increase the risk of serotonin toxicity/serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Remeron (mirtazapine). Whitehouse Station, NJ: Merck &amp; Co., Inc., 12/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6910":"<p><b>Title</b> Nilotinib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Nilotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction. If this combination must be used, do so with caution, monitoring the patient closely for evidence of nilotinib failure/inadequate response.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The average nilotinib AUC and maximum serum concentration were decreased by 34% and 27%, respectively, when a single dose of nilotinib (400 mg) was administered on day 6 of proton pump inhibitor esomeprazole (40 mg/day) administration (n=22).<sup>1</sup> The suspected mechanism of this interaction is a decrease in nilotinib solubility in the upper gastrointestinal tract due to the esomeprazole-mediated increase in gastric pH. Nilotinib solubility is known to be inversely related to gastric pH (i.e., solubility decreases with increasing pH).<sup>2</sup> The prescribing information recommends that the combination be used with caution since separation of doses is not likely to be an effective method of minimizing the interaction.<sup>2</sup><br><br>Of note, a retrospective analysis of 492 patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and 256 patients with imatinib-resistant or imatinib-intolerant Ph+ CML found no significant difference in clinical response to nilotinib between those receiving acid suppressing therapies (proton pump inhibitors in 18-30% of patients, H2 receptor antagonists in 7-10% of patients) and those not receiving any acid suppressing therapies.<sup>3</sup> The findings were not different when analyses were restricted to those patients using an acid suppressant for more than 50% of the time that they were receiving nilotinib, and an analysis of nilotinib serum concentrations found no difference in steady-state concentrations among those receiving acid suppressing medications.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemother Pharmacol</i>. 2012;70(2):345-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22623211\">[PubMed 22623211]</a></p>\n<p>2. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.</p>\n<p>3. Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. <i>J Clin Pharmacol</i>. 2010;50(8):960-967. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20498287\">[PubMed 20498287]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6911":"<p><b>Title</b> Nilotinib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> If concurrent use of an H2-receptor antagonist with nilotinib is necessary, the nilotinib dose should be given 10 hours after or 2 hours before the H2-receptor antagonist in order to minimize the risk of a significant interaction.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> The nilotinib AUC was not significantly altered when a single dose of nilotinib (400 mg) was administered 10 hours after or 2 hours before the H2-receptor antagonist (H2RA) famotidine (20 mg every 12 hours) in a study of 52 healthy volunteers.<sup>1</sup> Though clinical studies have not confirmed an interaction between H2RAs and nilotinib, one is expected since nilotinib solubility is known to decrease with increasing pH.<sup>2</sup> Data with the proton pump inhibitor esomeprazole support this, with the average nilotinib AUC and maximum serum concentration decreased by 34% and 27%, respectively, when a single dose of nilotinib (400 mg) was administered on day 6 of esomeprazole (40 mg/day) administration (n=22).<sup>3</sup><br><br>The prescribing information recommends that if an H2RA is necessary the nilotinib dose should be given 10 hours after or 2 hours before the H2RA.<sup>2</sup><br><br>Of note, a retrospective analysis of 492 patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and 256 patients with imatinib-resistant or imatinib-intolerant Ph+ CML found no significant difference in clinical response to nilotinib between those receiving acid suppressing therapies (proton pump inhibitors in 18-30% of patients, H2RAs in 7-10% of patients) and those not receiving any acid suppressing therapies.<sup>3</sup> The findings were not different when analyses were restricted to those patients using an acid suppressant for more than 50% of the time that they were receiving nilotinib, and an analysis of nilotinib serum concentrations found no difference in steady-state concentrations among those receiving acid suppressing medications.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yin OQ, Bedoucha V, McCulloch T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;71(1):219-226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23070146\">[PubMed 23070146]</a></p>\n<p>2. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2013.</p>\n<p>3. Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. <i>J Clin Pharmacol</i>. 2010;50(8):960-967. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20498287\">[PubMed 20498287]</a></p>\n<p>4. Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemother Pharmacol</i>. 2012;70(2):345-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22623211\">[PubMed 22623211]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6912":"<p><b>Title</b> Nilotinib / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Nilotinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> If concurrent use of an antacid with nilotinib is necessary, the nilotinib dose should be given 2 hours after or 2 hours before the antacid in order to minimize the risk of a significant interaction.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The nilotinib AUC was not significantly altered when a single dose of nilotinib (400 mg) was administered 2 hours after or 2 hours before an antacid (aluminum hydroxide/magnesium hydroxide/simethicone, 20 mL) in a study of 52 healthy volunteers.<sup>1</sup> Though clinical studies have not confirmed an interaction between antacids and nilotinib, one is expected since nilotinib solubility is known to decrease with increasing pH.<sup>2</sup> Data with the proton pump inhibitor esomeprazole support this, with the average nilotinib AUC and maximum serum concentration decreased by 34% and 27%, respectively, when a single dose of nilotinib (400 mg) was administered on day 6 of esomeprazole (40 mg/day) administration (n=22).<sup>3</sup><br><br>The prescribing information recommends that if an antacid is necessary the nilotinib dose should be given 2 hours after or 2 hours before administration of an antacid.<sup>2</sup><br><br>Of note, a retrospective analysis of 492 patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and 256 patients with imatinib-resistant or imatinib-intolerant Ph+ CML found no significant difference in clinical response to nilotinib between those receiving acid suppressing therapies (proton pump inhibitors in 18-30% of patients, H2RAs in 7-10% of patients) and those not receiving any acid suppressing therapies.<sup>3</sup> The findings were not different when analyses were restricted to those patients using an acid suppressant for more than 50% of the time that they were receiving nilotinib, and an analysis of nilotinib serum concentrations found no difference in steady-state concentrations among those receiving acid suppressing medications.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yin OQ, Bedoucha V, McCulloch T, et al. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2013;71(1):219-226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23070146\">[PubMed 23070146]</a></p>\n<p>2. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2013.</p>\n<p>3. Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. <i>J Clin Pharmacol</i>. 2010;50(8):960-967. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20498287\">[PubMed 20498287]</a></p>\n<p>4. Yin OQ, Giles FJ, Baccarani M, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. <i>Cancer Chemother Pharmacol</i>. 2012;70(2):345-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22623211\">[PubMed 22623211]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6913":"<p><b>Title</b> TraZODone / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of TraZODone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increase monitoring for signs/symptoms of trazodone toxicity (e.g., nausea, dizziness, hypotension, syncope) when using trazodone and boceprevir in combination. Dose reductions of trazodone may be necessary.</p> \n<p><b>Discussion</b> According to boceprevir prescribing information, concurrent use of boceprevir with trazodone may result in an increase in trazodone concentrations, though no specific data regarding this combination are provided.<sup>1</sup> The prescribing information further cautions that use of this combination may increase the risk for trazodone adverse effects and suggests consideration of a trazodone dose reduction.<br><br>The specific mechanism for this interaction is uncertain, but is likely boceprevir inhibition of the CYP3A-mediated metabolism of trazodone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 07/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6914":"<p><b>Title</b> Escitalopram / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may decrease the serum concentration of Escitalopram. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of reduced escitalopram effectiveness when used together with boceprevir. Although escitalopram dose adjustments are not expected to be required routinely, some escitalopram dose adjustments may be necessary.</p> \n<p><b>Discussion</b> According to boceprevir prescribing information, the escitalopram AUC and maximum serum concentration (Cmax) were reduced by an average of 21% and 19%, respectively, when a single dose of escitalopram (10 mg) was given to subjects receiving boceprevir (800 mg three times/day for 11 days).<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain. Boceprevir is a strong inhibitor of CYP3A and inhibits p-glycoprotein, but according to the boceprevir prescribing information, boceprevir is not an inhibitor or inducer of other cytochrome P450 enzymes.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 07/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6915":"<p><b>Title</b> Clarithromycin / Boceprevir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b> (CL<sub>cr</sub>&lt;60 mL/min): The significance of this interaction and the need for clarithromycin dose adjustment may be greater for patients with moderately or severely impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Clarithromycin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increase monitoring for signs/symptoms of toxicity from both drugs when this combination is used. Given the QT interval-prolonging potential of clarithromycin, excessive QT prolongation and the appearance of any new arrhythmias are of particular concern. Clarithromycin dose adjustments are not specifically recommended for patients with normal renal function. The specific dose adjustment for patients with impaired renal function are not specified, but the clarithromycin prescribing information recommends 50% or 75% dose reductions for patients with moderately or severely impaired renal function (creatine clearance of 30-60 mL/min or less than 30 mL/min), respectively, when clarithromycin is used in combination with the HIV protease inhibitors ritonavir or atazanavir.</p> \n<p><b>Discussion</b> According to the boceprevir prescribing information concurrent use of boceprevir and clarithromycin may be associated with increased concentrations of one or both drugs, though no specific data regarding this combination are provided.<sup>1</sup> Caution and increased monitoring are recommended, with the QT-prolonging potential of clarithromycin as a particular concern. Also, though not included in the prescribing information warning, decreased concentrations of the active 14-hydroxy-clarithromycin metabolite may negatively impact its effectiveness against certain organisms. Clarithromycin dose adjustments are not specifically recommended for patients with normal renal function. The specific dose adjustment for patients with impaired renal function are not specified, but the clarithromycin prescribing information recommends 50% or 75% dose reductions for patients with moderately or severely impaired renal function (creatine clearance of 30-60 mL/min or less than 30 mL/min), respectively, when clarithromycin is used in combination with the HIV protease inhibitors ritonavir or atazanavir.<sup>2</sup><br><br>The exact mechanism(s) for this potential interaction is(are) unclear. Both boceprevir and clarithromycin are inhibitors and substrates for CYP3A, suggesting that each drug could inhibit the other drug's metabolism, leading to increased concentrations and the possibility of increased toxicities.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 07/2012.</p>\n<p>2. Prescribing information. Biaxin (clarithromycin). North Chicago, IL: Abbott Laboratories, 07/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6916":"<p><b>Title</b> Pravastatin / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Pravastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of pravastatin toxicity when used together with boceprevir. In particular, monitor patients closely for evidence of muscle toxicity (e.g., pain, tenderness, weakness, elevated CPK, etc.) and increased liver function tests.</p> \n<p><b>Discussion</b> The pravastatin AUC and maximum serum concentration (Cmax) were increased by an average of 63% and 49%, respectively, when a single dose of pravastatin (40 mg) was given to healthy subjects receiving boceprevir (800 mg three times/day for 6 days).<sup>1</sup><br><br>The specific mechanism for this interaction is uncertain. Boceprevir is a strong inhibitor of CYP3A,<sup>2</sup> but pravastatin undergoes little CYP3A-mediated metabolism. According to in vitro studies, boceprevir may also inhibit the drug efflux transporter p-glycoprotein and the hepatic uptake transporter SLCO1B1 (aka OATP1B1),<sup>2,3</sup> both of which may be at least partially involved in the distribution and elimination of pravastatin, potentially serving as a mechanism for this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hulskotte E, Feng HP, Xuan F, et al, “Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin,” <i>Antimicrob Agents Chemother</i>, 2013, Mar 25 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23529734\">[PubMed 23529734]</a></p>\n<p>2. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 02/2013.</p>\n<p>3. Chu X, Cai X, Cui D, et al, “In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters,” <i>Drug Metab Dispos</i>, 2013, 41(3):668-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23293300\">[PubMed 23293300]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6918":"<p><b>Title</b> CycloSPORINE (Systemic) / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Cyclosporine dose adjustments will likely be necessary when used together with boceprevir. Monitor serum cyclosporine concentrations closely following the initiation of boceprevir, and follow patients closely for evidence of cyclosporine toxicity (eg, nephrotoxicity, etc.).</p> \n<p><b>Discussion</b> The cyclosporine AUC and maximum serum concentration (Cmax) were an average of 2.7-fold and 2-fold higher, respectively, when a single dose of cyclosporine (100 mg) was given to subjects receiving boceprevir (800 mg 3 times daily for 7 days).<sup>1,2</sup> Additionally, the oral clearance of cyclosporine was reduced 50% during the first week after administration of boceprevir 800 mg 3 times daily in liver transplant patients who had achieved a steady state of immunosuppressive therapy before the initiation of boceprevir.<sup>3</sup> Results were confirmed in a similar study showing that patients treated with boceprevir 800 mg 3 times daily required their cyclosporine dose to be reduced to approximately 50% of the original dose to maintain therapeutic cyclosporine serum concentrations.<sup>4</sup> The specific mechanism for this interaction is uncertain but likely involves boceprevir inhibition of the CYP3A metabolism of cyclosporine.<sup>1,2,3,4</sup><br><br>The boceprevir AUC was increased by an average of 16% following a single dose of cyclosporine (100 mg). The clinical significance of this increase is uncertain. The likely mechanism is inhibition of CYP3A-mediated boceprevir metabolism by cyclosporine. Boceprevir is primarily metabolized via a non-cytochrome P450 route, with only partial metabolism via CYP3A,<sup>1</sup> which explains the relatively minor effects observed with cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Victrelis (boceprevir). [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; January 2017.</p>\n<p>2. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. <i>Hepatology</i>. 2012;56(5):1622-1630. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22576324\">[PubMed 22576324]</a></p>\n<p>3. Coilly A, Furlan V, Roche B, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. <i>Antimicrob Agents Chemother</i>. 2012;56(11):5728-5734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22908172\">[PubMed 22908172]</a></p>\n<p>4. Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. <i> Liver Transpl</i>. 2013;19(7):690-700. [Pub Med 23696372]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6920":"<p><b>Title</b> Tacrolimus (Systemic) / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Tacrolimus doses will need to be substantially reduced, and the tacrolimus dosing interval will likely need to be prolonged with concurrent use of boceprevir. Monitor serum tacrolimus concentrations closely, and follow patients closely for evidence of tacrolimus toxicity (e.g., nephrotoxicity, etc.).</p> \n<p><b>Discussion</b> The tacrolimus AUC and maximum serum concentration (Cmax) were an average of 17.1-fold and 9.9-fold higher, respectively, when a single dose of tacrolimus (0.5 mg) was given to subjects receiving boceprevir (800 mg three times/day for 11 days).<sup>1,2</sup> Additionally, the oral clearance of tacrolimus was reduced up to 80% during the first week after administration of boceprevir 800 mg TID in liver transplant patients who had achieved a steady state of immunosuppressive therapy before the initiation of boceprevir.<sup>3</sup> The specific mechanism for this interaction is uncertain but likely involves boceprevir inhibition of the CYP3A metabolism of tacrolimus.<sup>1,2,3</sup><br><br>Of note, the single dose of tacrolimus (0.5 mg) did not result in any significant changes in boceprevir concentrations.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Victrelis (boceprevir). [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; January 2017.</p>\n<p>2. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. <i>Hepatology</i>. 2012;56(5):1622-1630. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22576324\">[PubMed 22576324]</a></p>\n<p>3. Coilly A, Furlan V, Roche B, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. <i>Antimicrob Agents Chemother</i>. 2012;56(11):5728-5734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22908172\">[PubMed 22908172]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6921":"<p><b>Title</b> Sirolimus / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Significant sirolimus dose reductions and prolongation of the sirolimus dosing interval will likely be required if used with boceprevir. If this combination is used, monitor sirolimus concentrations and clinical response closely.</p> \n<p><b>Discussion</b> According to the boceprevir prescribing information, the sirolimus AUC and maximum serum concentration (Cmax) were an average of 8.1- and 4.8-fold higher, respectively, when sirolimus (2 mg single dose) was administered to subjects pre-treated with boceprevir (800 mg three times/day x 9 days).<sup>1</sup> Also, studies with the somewhat similar agent tacrolimus reported an average 17.1-fold increase in tacrolimus AUC when a single dose of tacrolimus (0.5 mg) was given to subjects taking boceprevir (800 mg three times/day for 11 days).<sup>1</sup><br><br>The mechanism(s) for this predicted interaction involves boceprevir inhibition of the CYP3A-mediated metabolism and/or p-glycoprotein-mediated transport of sirolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 09/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6923":"<p><b>Title</b> Dihydroergotamine / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with dihydroergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of telaprevir with dihydroergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of telaprevir to inhibit CYP3A, which plays a significant role in the metabolism of dihydroergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6925":"<p><b>Title</b> Dihydroergotamine / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of dihydroergotamine with ketoconazole is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of dihydroergotamine with ketoconazole is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of ketoconazole to inhibit CYP3A, which plays a significant role in the metabolism of dihydroergotamine.<sup>1</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6926":"<p><b>Title</b> Dihydroergotamine / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of itraconazole with dihydroergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of itraconazole with dihydroergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of itraconazole to inhibit CYP3A, which plays a significant role in the metabolism of dihydroergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sporanox (itraconazole). Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., March 2009.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6927":"<p><b>Title</b> Dihydroergotamine / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of posaconazole with dihydroergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of posaconazole with dihydroergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of posaconazole to inhibit CYP3A, which plays a significant role in the metabolism of dihydroergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering-Plough, 6/2012.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6928":"<p><b>Title</b> Dihydroergotamine / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of voriconazole with dihydroergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of voriconazole with dihydroergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of voriconazole to inhibit CYP3A, which plays a significant role in the metabolism of dihydroergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. VFend (voriconazole). New York, NY: Pfizer Inc., 10/2011.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6930":"<p><b>Title</b> Ergotamine / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with ergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of telaprevir with ergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of telaprevir to inhibit CYP3A, which plays a significant role in the metabolism of ergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p>2. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6932":"<p><b>Title</b> Ergotamine / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of ergotamine with ketoconazole is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of ergotamine with ketoconazole is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of ketoconazole to inhibit CYP3A, which plays a significant role in the metabolism of ergotamine.<sup>1</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6933":"<p><b>Title</b> Ergotamine / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of itraconazole with ergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of itraconazole with ergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of itraconazole to inhibit CYP3A, which plays a significant role in the metabolism of ergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sporanox (itraconazole). Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., March 2009.</p>\n<p>2. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6934":"<p><b>Title</b> Ergotamine / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of posaconazole with ergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of posaconazole with ergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of posaconazole to inhibit CYP3A, which plays a significant role in the metabolism of ergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering-Plough, 6/2012.</p>\n<p>2. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6935":"<p><b>Title</b> Ergotamine / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of voriconazole with ergotamine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of voriconazole with ergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of voriconazole to inhibit CYP3A, which plays a significant role in the metabolism of ergotamine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. VFend (voriconazole). New York, NY: Pfizer Inc., 10/2011.</p>\n<p>2. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6937":"<p><b>Title</b> Methylergonovine / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Methylergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with methyergonovine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of telaprevir with methylergonovine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of telaprevir to inhibit CYP3A, which plays a significant role in the metabolism of methylergonovine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p>2. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6939":"<p><b>Title</b> Methylergonovine / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Methylergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of methylergonovine with ketoconazole is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of methylergonovine with ketoconazole is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of ketoconazole to inhibit CYP3A, which plays a significant role in the metabolism of methylergonovine.<sup>1</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6940":"<p><b>Title</b> Methylergonovine / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Methylergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of itraconazole with methyergonovine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of itraconazole with methylergonovine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of itraconazole to inhibit CYP3A, which plays a significant role in the metabolism of methylergonovine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sporanox (itraconazole). Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., March 2009.</p>\n<p>2. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6941":"<p><b>Title</b> Methylergonovine / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Methylergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of posaconazole with methyergonovine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of posaconazole with methylergonovine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of posaconazole to inhibit CYP3A, which plays a significant role in the metabolism of methylergonovine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering-Plough, 6/2012.</p>\n<p>2. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6942":"<p><b>Title</b> Methylergonovine / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Methylergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of voriconazole with methylergonovine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of voriconazole with methylergonovine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of voriconazole to inhibit CYP3A, which plays a significant role in the metabolism of methylergonovine.<sup>1,2</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. VFend (voriconazole). New York, NY: Pfizer Inc., 10/2011.</p>\n<p>2. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>3. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>4. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6944":"<p><b>Title</b> Ergonovine / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Ergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of telaprevir with ergonovine should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of telaprevir with ergonovine should be avoided due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of telaprevir to inhibit CYP3A, which plays a significant role in the metabolism of many ergot derivatives such as ergonovine.<sup>1,2,3,4</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>4. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>5. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>6. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6946":"<p><b>Title</b> Ergonovine / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Ergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of ketoconazole with ergonovine should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of ketoconazole with ergonovine should be avoided due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.). This interaction is predicted based on the ability of ketoconazole to inhibit CYP3A, which plays a significant role in the metabolism of many ergot derivatives such as ergonovine.<sup>1,2,3</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>2. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>3. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>4. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>5. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6947":"<p><b>Title</b> Ergonovine / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Ergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of itraconazole with ergonovine should be avoided due to the potential for ergot toxicity. Itraconazole US prescribing information specifically lists this as a contraindication.</p> \n<p><b>Discussion</b> Concurrent use of itraconazole with ergonovine should be avoided due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of itraconazole to inhibit CYP3A, which plays a significant role in the metabolism of many ergot derivatives such as ergonovine.<sup>1,2,3,4</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sporanox</i> (itraconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; June 2014.</p>\n<p>2. <i>DHE 45</i> (dihydroergotamine) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals North America; July 2002.</p>\n<p>3. <i>Methergine</i> (methylergonovine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2012.</p>\n<p>4. <i>Cafergot</i> (ergotamine and caffeine) [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada Inc; August 2007.</p>\n<p>5. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. <i>Postgrad Med J</i>. 1999;75(887):546-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>6. Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. <i>Antimicrob Agents Chemother</i>. 1997;41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6948":"<p><b>Title</b> Ergonovine / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Ergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of posaconazole with ergonovine should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of posaconazole with ergonovine should be avoided due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of posaconazole to inhibit CYP3A, which plays a significant role in the metabolism of many ergot derivatives such as ergonovine.<sup>1,2,3,4</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Noxafil (posaconazole). Kenilworth, NJ: Schering-Plough, 6/2012.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>4. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>5. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>6. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6949":"<p><b>Title</b> Ergonovine / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Ergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of voriconazole with ergonovine should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of voriconazole with ergonovine should be avoided due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of voriconazole to inhibit CYP3A, which plays a significant role in the metabolism of many ergot derivatives such as ergonovine.<sup>1,2,3,4</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. VFend (voriconazole). New York, NY: Pfizer Inc., 10/2011.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>4. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>5. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>6. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6950":"<p><b>Title</b> Ergonovine / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Ergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of boceprevir with ergonovine is contraindicated due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of boceprevir with ergonovine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc.).<sup>1</sup><br><br>This interaction is predicted based on the ability of boceprevir to inhibit CYP3A, which plays a significant role in the metabolism of many ergot derivatives such as ergonovine.<sup>1,2,3,4</sup> Though specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p>2. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>3. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>4. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p>5. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>6. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6952":"<p><b>Title</b> Ergoloid Mesylates / Telaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Ergoloid Mesylates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ergoloid mesylates with telaprevir should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> This specific interaction is predicted based on the ability of telaprevir to inhibit CYP3A. Though specific data regarding this combination are not available, one study has documented a substantial pharmacokinetic interaction between an individual constituent of the ergoloid mesylates and the moderate CYP3A inhibitor erythromycin,<sup>1</sup> and there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup><br><br>Ergoloid mesylates are comprised of dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine.<sup>4</sup> The AUC and maximum serum concentration (Cmax) of dihydroergocryptine were an average of 16.5- and 9.5-fold higher, respectively, following coadministration of erythromycin (500 mg three times/day) with dihydroergocryptine (10 mg) in a study of 9 healthy volunteers.<sup>1</sup> The mechanism for this apparent interaction is inhibition of the CYP3A-mediated metabolism of dihydroergocryptine.<sup>1,5</sup><br><br>Though the specific routes of metabolism for dihydroergocristine and dihydroergocornine are unclear, the apparently significant role for CYP3A in the metabolism of dihydroergocryptine and other related ergot alkaloids suggests a similar dependence on CYP3A.<sup>5,6,7,8</sup> Similarly, although ergoloid mesylates may not be specifically listed in the labeling of products that contraindicate (or recommend avoiding) use with ergot alkoids, the likely similar potential for a significant interaction suggests that similar caution should be applied to the ergoloid mesylates.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Mey C, Althaus M, Ezan E, et al, “Erythromycin Increases Plasma Concentrations of Alpha-Dihydroergocryptine in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):142-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>4. Prescribing information. Ergoloid mesylates. Philadelphia, PA: Mutual Pharmaceutical Co., Inc., January 2009.</p>\n<p>5. Althaus M, Retzow A, Castell JV, et al, “In Vitro Identification of the Cytochrome P450 Isoform Responsible for the Metabolism of Alpha-Dihydroergocryptine,” <i>Xenobiotica</i>, 2000, 30(11):1033-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197065\">[PubMed 11197065]</a></p>\n<p>6. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>7. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>8. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6954":"<p><b>Title</b> Ergoloid Mesylates / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Ergoloid Mesylates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ergoloid mesylates with ketoconazole should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> This specific interaction is predicted based on the ability of ketoconazole to inhibit CYP3A. Though specific data regarding this combination are not available, onse study has documented a substantial pharmacokinetic interaction between an individual constituent of the ergoloid mesylates and the moderate CYP3A inhibitor erythromycin,<sup>1</sup> and there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup><br><br>Ergoloid mesylates are comprised of dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine.<sup>4</sup> The AUC and maximum serum concentration (Cmax) of dihydroergocryptine were an average of 16.5- and 9.5-fold higher, respectively, following coadministration of erythromycin (500 mg three times/day) with dihydroergocryptine (10 mg) in a study of 9 healthy volunteers.<sup>1</sup> The mechanism for this apparent interaction is inhibition of the CYP3A-mediated metabolism of dihydroergocryptine.<sup>1,5</sup><br><br>Though the specific routes of metabolism for dihydroergocristine and dihydroergocornine are unclear, the apparently significant role for CYP3A in the metabolism of dihydroergocryptine and other related ergot alkaloids suggests a similar dependence on CYP3A.<sup>5,6,7,8</sup> Similarly, although ergoloid mesylates may not be specifically listed in the labeling of products that contraindicate (or recommend avoiding) use with ergot alkoids, the likely similar potential for a significant interaction suggests that similar caution should be applied to the ergoloid mesylates.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Mey C, Althaus M, Ezan E, et al, “Erythromycin Increases Plasma Concentrations of Alpha-Dihydroergocryptine in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):142-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>4. Prescribing information. Ergoloid mesylates. Philadelphia, PA: Mutual Pharmaceutical Co., Inc., January 2009.</p>\n<p>5. Althaus M, Retzow A, Castell JV, et al, “In Vitro Identification of the Cytochrome P450 Isoform Responsible for the Metabolism of Alpha-Dihydroergocryptine,” <i>Xenobiotica</i>, 2000, 30(11):1033-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197065\">[PubMed 11197065]</a></p>\n<p>6. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>7. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>8. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6955":"<p><b>Title</b> Ergoloid Mesylates / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Ergoloid Mesylates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ergoloid mesylates with itraconazole should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> This specific interaction is predicted based on the ability of itraconazole to inhibit CYP3A. Though specific data regarding this combination are not available, onse study has documented a substantial pharmacokinetic interaction between an individual constituent of the ergoloid mesylates and the moderate CYP3A inhibitor erythromycin,<sup>1</sup> and there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup><br><br>Ergoloid mesylates are comprised of dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine.<sup>4</sup> The AUC and maximum serum concentration (Cmax) of dihydroergocryptine were an average of 16.5- and 9.5-fold higher, respectively, following coadministration of erythromycin (500 mg three times/day) with dihydroergocryptine (10 mg) in a study of 9 healthy volunteers.<sup>1</sup> The mechanism for this apparent interaction is inhibition of the CYP3A-mediated metabolism of dihydroergocryptine.<sup>1,5</sup><br><br>Though the specific routes of metabolism for dihydroergocristine and dihydroergocornine are unclear, the apparently significant role for CYP3A in the metabolism of dihydroergocryptine and other related ergot alkaloids suggests a similar dependence on CYP3A.<sup>5,6,7,8</sup> Similarly, although ergoloid mesylates may not be specifically listed in the labeling of products that contraindicate (or recommend avoiding) use with ergot alkoids, the likely similar potential for a significant interaction suggests that similar caution should be applied to the ergoloid mesylates.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Mey C, Althaus M, Ezan E, et al, “Erythromycin Increases Plasma Concentrations of Alpha-Dihydroergocryptine in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):142-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>4. Prescribing information. Ergoloid mesylates. Philadelphia, PA: Mutual Pharmaceutical Co., Inc., January 2009.</p>\n<p>5. Althaus M, Retzow A, Castell JV, et al, “In Vitro Identification of the Cytochrome P450 Isoform Responsible for the Metabolism of Alpha-Dihydroergocryptine,” <i>Xenobiotica</i>, 2000, 30(11):1033-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197065\">[PubMed 11197065]</a></p>\n<p>6. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>7. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>8. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6956":"<p><b>Title</b> Ergoloid Mesylates / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Ergoloid Mesylates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ergoloid mesylates with posaconazole should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> This specific interaction is predicted based on the ability of posaconazole to inhibit CYP3A. Though specific data regarding this combination are not available, onse study has documented a substantial pharmacokinetic interaction between an individual constituent of the ergoloid mesylates and the moderate CYP3A inhibitor erythromycin,<sup>1</sup> and there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup><br><br>Ergoloid mesylates are comprised of dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine.<sup>4</sup> The AUC and maximum serum concentration (Cmax) of dihydroergocryptine were an average of 16.5- and 9.5-fold higher, respectively, following coadministration of erythromycin (500 mg three times/day) with dihydroergocryptine (10 mg) in a study of 9 healthy volunteers.<sup>1</sup> The mechanism for this apparent interaction is inhibition of the CYP3A-mediated metabolism of dihydroergocryptine.<sup>1,5</sup><br><br>Though the specific routes of metabolism for dihydroergocristine and dihydroergocornine are unclear, the apparently significant role for CYP3A in the metabolism of dihydroergocryptine and other related ergot alkaloids suggests a similar dependence on CYP3A.<sup>5,6,7,8</sup> Similarly, although ergoloid mesylates may not be specifically listed in the labeling of products that contraindicate (or recommend avoiding) use with ergot alkoids, the likely similar potential for a significant interaction suggests that similar caution should be applied to the ergoloid mesylates.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Mey C, Althaus M, Ezan E, et al, “Erythromycin Increases Plasma Concentrations of Alpha-Dihydroergocryptine in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):142-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>4. Prescribing information. Ergoloid mesylates. Philadelphia, PA: Mutual Pharmaceutical Co., Inc., January 2009.</p>\n<p>5. Althaus M, Retzow A, Castell JV, et al, “In Vitro Identification of the Cytochrome P450 Isoform Responsible for the Metabolism of Alpha-Dihydroergocryptine,” <i>Xenobiotica</i>, 2000, 30(11):1033-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197065\">[PubMed 11197065]</a></p>\n<p>6. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>7. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>8. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6957":"<p><b>Title</b> Ergoloid Mesylates / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Ergoloid Mesylates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ergoloid mesylates with voriconazole should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> This specific interaction is predicted based on the ability of voriconazole to inhibit CYP3A. Though specific data regarding this combination are not available, one study has documented a substantial pharmacokinetic interaction between an individual constituent of the ergoloid mesylates and the moderate CYP3A inhibitor erythromycin,<sup>1</sup> and there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup><br><br>Ergoloid mesylates are comprised of dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine.<sup>4</sup> The AUC and maximum serum concentration (Cmax) of dihydroergocryptine were an average of 16.5- and 9.5-fold higher, respectively, following coadministration of erythromycin (500 mg three times/day) with dihydroergocryptine (10 mg) in a study of 9 healthy volunteers.<sup>1</sup> The mechanism for this apparent interaction is inhibition of the CYP3A-mediated metabolism of dihydroergocryptine.<sup>1,5</sup><br><br>Though the specific routes of metabolism for dihydroergocristine and dihydroergocornine are unclear, the apparently significant role for CYP3A in the metabolism of dihydroergocryptine and other related ergot alkaloids suggests a similar dependence on CYP3A.<sup>5,6,7,8</sup> Similarly, although ergoloid mesylates may not be specifically listed in the labeling of products that contraindicate (or recommend avoiding) use with ergot alkoids, the likely similar potential for a significant interaction suggests that similar caution should be applied to the ergoloid mesylates.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Mey C, Althaus M, Ezan E, et al, “Erythromycin Increases Plasma Concentrations of Alpha-Dihydroergocryptine in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):142-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>4. Prescribing information. Ergoloid mesylates. Philadelphia, PA: Mutual Pharmaceutical Co., Inc., January 2009.</p>\n<p>5. Althaus M, Retzow A, Castell JV, et al, “In Vitro Identification of the Cytochrome P450 Isoform Responsible for the Metabolism of Alpha-Dihydroergocryptine,” <i>Xenobiotica</i>, 2000, 30(11):1033-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197065\">[PubMed 11197065]</a></p>\n<p>6. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>7. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>8. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6958":"<p><b>Title</b> Ergoloid Mesylates / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Boceprevir may increase the serum concentration of Ergoloid Mesylates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ergoloid mesylates with boceprevir should be avoided due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> This specific interaction is predicted based on the ability of boceprevir to inhibit CYP3A. Though specific data regarding this combination are not available, one study has documented a substantial pharmacokinetic interaction between an individual constituent of the ergoloid mesylates and the moderate CYP3A inhibitor erythromycin,<sup>1</sup> and there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>2,3</sup><br><br>Ergoloid mesylates are comprised of dihydroergocristine, dihydroergocornine, and alpha- and beta-dihydroergocryptine.<sup>4</sup> The AUC and maximum serum concentration (Cmax) of dihydroergocryptine were an average of 16.5- and 9.5-fold higher, respectively, following coadministration of erythromycin (500 mg three times/day) with dihydroergocryptine (10 mg) in a study of 9 healthy volunteers.<sup>1</sup> The mechanism for this apparent interaction is inhibition of the CYP3A-mediated metabolism of dihydroergocryptine.<sup>1,5</sup><br><br>Though the specific routes of metabolism for dihydroergocristine and dihydroergocornine are unclear, the apparently significant role for CYP3A in the metabolism of dihydroergocryptine and other related ergot alkaloids suggests a similar dependence on CYP3A.<sup>5,6,7,8</sup> Similarly, although ergoloid mesylates may not be specifically listed in the labeling of products that contraindicate (or recommend avoiding) use with ergot alkoids, the likely similar potential for a significant interaction suggests that similar caution should be applied to the ergoloid mesylates.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Mey C, Althaus M, Ezan E, et al, “Erythromycin Increases Plasma Concentrations of Alpha-Dihydroergocryptine in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(2):142-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503008\">[PubMed 11503008]</a></p>\n<p>2. Blanche P, Rigolet A, Gombert B, et al, “Ergotism Related to a Single Dose of Ergotamine Tartrate in an AIDS Patient Treated with Ritonavir,” <i>Postgrad Med J</i>, 1999, 75(887):546-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>3. Caballero-Granado FJ, Viciana P, Cordero E, et al, “Ergotism Related to Concurrent Administration of Ergotamine Tartrate and Ritonavir in an AIDS Patient,” <i>Antimicrob Agents Chemother</i>, 1997, 41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p>4. Prescribing information. Ergoloid mesylates. Philadelphia, PA: Mutual Pharmaceutical Co., Inc., January 2009.</p>\n<p>5. Althaus M, Retzow A, Castell JV, et al, “In Vitro Identification of the Cytochrome P450 Isoform Responsible for the Metabolism of Alpha-Dihydroergocryptine,” <i>Xenobiotica</i>, 2000, 30(11):1033-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11197065\">[PubMed 11197065]</a></p>\n<p>6. Prescribing information. D.H.E. 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, 7/2002.</p>\n<p>7. Prescribing information. Methergine (methylergonovine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, June 2012.</p>\n<p>8. Product monograph. Cafergot (ergotamine and caffeine). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., August 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6959":"<p><b>Title</b> Etoposide / Echinacea</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Echinacea may increase the serum concentration of Etoposide. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased etoposide effects/toxicity when used together with echinacea.</p> \n<p><b>Discussion</b> A published case report describes a 61-year-old man with non-small cell lung cancer who experienced profound thrombocytopenia, requiring platelet transfusion, following his first cycle of treatment with cisplatin and etoposide.<sup>1</sup> It was subsequently discovered that the patient had been self-treating with echinacea, which was discontinued prior to the second chemotherapy cycle. Following this second cycle, the patient again experienced thrombocytopenia but to a lesser degree that did not require any platelet transfusion. The authors of the report theorized that this severe initial thrombocytopenia was the result of an interaction between echinacea and etoposide, where the echinacea inhibited the CYP3A-mediated metabolism of etoposide, leading to greater etoposide concentrations and effects.<sup>1</sup><br><br>The degree to which echinacea is capable to altering CYP3A activity is unclear. Several studies have evaluated this effect in vitro and in vivo, resulting in largely discrepant findings. Echinacea treatment (500 mg three times/day for 14 days with lopinavir/ritonavir and 14 days alone) was associated with an average 27% decrease in midazolam AUC (as a marker of CYP3A activity) and an average 37% increase in the midazolam oral clearance in a study of 13 healthy volunteers, suggesting that echinacea increased CYP3A activity.<sup>2</sup> Somewhat similarly, echinacea treatment (400 mg four times/day for 8 days) was associated with an average 23% decrease in midazolam AUC and an average 34% increase in midazolam clearance following IV administration of midazolam.<sup>3</sup> However, the oral clearance of midazolam was not significantly altered, with additional analysis suggesting that echinacea increased hepatic metabolism of midazolam but inhibited intestinal metabolism of oral midazolam. In vitro studies have also largely found mixed evidence for relatively weak-moderate CYP3A induction and inhibition.<sup>4,5,6</sup><br><br>Given this case report and the variable evidence for echinacea-mediated CYP3A induction and/or inhibition, caution would be prudent with concurrent use of any CYP3A substrate (and particularly with agents that have a narrow therapeutic index).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bossaer JB, Odle BL, “Probable Etoposide Interaction with Echinacea,” <i>J Diet Suppl</i>, 2012, 9(2):90-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22607644\">[PubMed 22607644]</a></p>\n<p>2. Penzak SR, Robertson SM, Hunt JD, et al, “Echinacea Purpurea Significantly Induces Cytochrome P450 3A Activity But Does Not Alter Lopinavir-Ritonavir Exposure in Healthy Subjects,” <i>Pharmacotherapy</i>, 2010, 30(8):797-805. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653355\">[PubMed 20653355]</a></p>\n<p>3. Gorski JC, Huang SM, Pinto A, et al, “The Effect of Echinacea (Echinacea Purpurea Root) on Cytochrome P450 Activity In Vivo,” <i>Clin Pharmacol Ther</i>, 2004, 75(1):89-100. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14749695\">[PubMed 14749695]</a></p>\n<p>4. Hansen TS, Nilsen OG, “In Vitro CYP3A4 Metabolism: Inhibition by Echinacea Purpurea and Choice of Substrate for the Evaluation of Herbal Inhibition,” <i>Basic Clin Pharmacol Toxicol</i>, 2008, 103(5):445-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18947363\">[PubMed 18947363]</a></p>\n<p>5. Gurley BJ, Gardner SF, Hubbard MA, et al, “In Vivo Assessment of Botanical Supplementation on Human Cytochrome P450 Phenotypes: Citrus Aurantium, Echinacea Purpurea, Milk Thistle, and Saw Palmetto,” <i>Clin Pharmacol Ther</i>, 2004, 76(5):428-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15536458\">[PubMed 15536458]</a></p>\n<p>6. Yale SH, Glurich I, “Analysis of the Inhibitory Potential of Ginkgo Biloba, Echinacea Purpurea, and Serenoa Repens on the Metabolic Activity of Cytochrome P450 3A4, 2D6, and 2C9,” <i>J Altern Complement Med</i>, 2005, 11(3):433-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15992226\">[PubMed 15992226]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6972":"<p><b>Title</b> VinCRIStine (Liposomal) / NIFEdipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> NIFEdipine may increase the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased vincristine toxicity in patients receiving nifedipine.</p> \n<p><b>Discussion</b> In a clinical study of patients with solid tumors, the AUC and terminal half-life of vincristine (2 mg) were approximately fourfold greater in 12 patients receiving nifedipine (10 mg 3 times daily beginning 3 days before vincristine and continuing for 7 days afterwards) compared to a control group not treated with nifedipine.<sup>1</sup> The volume of distribution was unchanged, and no untoward clinical effects were noted. A single published case report describes significant neurologic toxicity in a patient receiving vincristine, nifedipine, and itraconazole, although the role of nifedipine specifically in this case is uncertain as itraconazole is also strongly suspected to interact with vincristine.<sup>2</sup><br><br>The mechanism of this interaction is unclear. Nifedipine could theoretically increase systemic concentrations of vincristine via reducing its p-glycoprotein mediated efflux.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fedeli L, Colozza M, Boschetti E, et al, “Pharmacokinetics of Vincristine in Cancer Patients Treated with Nifedipine,” <i>Cancer</i>, 1989, 64(9):1805-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2790693\">[PubMed 2790693]</a></p>\n<p>2. Sathiapalan RK and El-Solh H, “Enhanced Vincristine Neurotoxicity From Drug Interactions: Case Report and Review of Literature,” <i>Pediatr Hematol Oncol</i>, 2001, 18(8):543-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11764105\">[PubMed 11764105]</a></p>\n<p>3. Ferry DR, Russell MA, and Cullen MH, “P-glycoprotein Possesses a 1,4-Dihydropyridine-Selective Drug Acceptor Site Which Is Alloserically Coupled to a Vinca-Alkaloid-Selective Binding Site,” <i>Biochem Biophys Res Commun</i>, 1992, 188(1):440-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1358068\">[PubMed 1358068]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6973":"<p><b>Title</b> VinCRIStine (Liposomal) / Teniposide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teniposide may enhance the neurotoxic effect of VinCRIStine (Liposomal). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients closely for signs and symptoms of neuropathy and/or neurotoxicity, and caution patients to promptly report any signs or symptoms of neuropathy/neurotoxicity. Patients with a pre-existing neuopathy or history of neuropathies may be at greater risk. When possible, consider alternative treatments, particularly in high-risk patients. Potential benefit of treatment should outweigh the risks.</p> \n<p><b>Discussion</b> Teniposide prescribing information cautions that concurrent use of teniposide and vincristine may be associated with an increased risk of neurotoxicity, possibly including severe neuropathy.<sup>1</sup> Several clinical studies have documented a particularly high occurrence of neurotoxicity when vincristine is used with teniposide.<sup>2,3,4,5</sup> Although vincristine use has been independently associated with relatively high rates of neurotoxicity, neurotoxicity has not been frequently reported with teniposide use.<sup>1,2</sup> However, a randomized study of 164 subjects found that teniposide was free from neurotoxicity when used without vincristine, but moderate to severe neurotoxicity occurred in almost half the patients treated with teniposide and vincristine.<sup>2</sup> A follow-up study looking at additive therapeutic effects of vincristine and teniposide revealed a statistically and clinically significant increase in neurotoxicity when these agents were combined, without a significant increase in treatment efficacy.<sup>3</sup> Grade 2 and 3 neurotoxicity occurred in 20% of patients receiving both vincristine and teniposide, versus 8% of patients receiving only vincristine and 0% of patients receiving only teniposide.<sup>3</sup> A small study of 9 patients with diffuse cell lymphoma directly investigated the neurotoxic potential of vincristine in combination with teniposide.<sup>4</sup> Neurotoxicity was most commonly reported as symmetrical parasthesia with little or no objective sensory deficit, and occurred in 8 patients (89%). In 4 patients there was a more severe sudden onset of weakness, with patchy asymmetrical motor loss. Deep tendon reflexes were absent in the legs and severely diminished in the arms.<sup>4</sup> In a later study, teniposide in combination with vincristine, cisplatin, and cyclophosphamide was administered to 11 patients with adrenocortical cancer. Peripheral neuropathy occurred in 8 of the 10 patients and 24 of the 60 chemotherapy cycles included in the final analysis; one patient required a 50% reduction in vincristine dose for one cycle and six patients required withdrawal of vincristine in a total of 18 cycles.<sup>5</sup> In contrast to these studies, one study of 56 children whose acute lymphocytic leukemia was treated with combination vincristine and teniposide did not indicate abnormally high rates of neurotoxicity.<sup>6</sup><br><br>The mechanism by which teniposide increases the neurotoxic potential of vincristine is unclear. Teniposide alone does not appear to cause neurotoxicity, nor is it thought to directly interact with the mechanism by which vincristine causes neurotoxicity (inhibition of tubulin dimer polymerization into microtubules involved in axoplasmic transport).<sup>7</sup> It has been postulated that prior or simultaneous administration of teniposide may increase the tubulin’s affinity for vincristine, or make the tubulin more sensitive to the depolymerizing effect of vincristine.<sup>4</sup> Cytochrome P450 (CYP) involvement may play a role in the increased incidence of neurotoxicity seen when vincristine is combined with teniposide. Increased incidence of neurotoxocity has been noted in patients with poor expression of CYP3A5.<sup>8</sup> It has been established that teniposide is metabolized primarily by CYP3A4, but also CYP3A5 to a lesser extent, creating at least a potential for competitive inhibition.<sup>9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Vumon (teniposide). Princeton, NJ: Bristol-Myers Squibb Company, December 2010.</p>\n<p>2. Anonymous, “Comparison of the Use of Teniposide and Vincristine in Combination Chemotherapy for Non-Hodgkin’s Lymphoma. The Australian and New Zealand Lymphoma Co-operative Chemotherapy Study Group”, <i>Cancer Treat Rep</i>, 1982, 66(1):49-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7053265\">[PubMed 7053265]</a></p>\n<p>3. Anonymous, “Investigation of the Additive Potential of Teniposide and Vincristine in Non-Hodgkin's Lymphoma. The Australian and New Zealand Lymphoma Co-operative Chemotherapy Study Group,” <i>Cancer Treat Rep</i>, 1986, 70(8): 985-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2873890\">[PubMed 2873890]</a></p>\n<p>4. Griffiths JD, Stark RJ, Ding JC, et al, “Vincristine Neurotoxicity Enhanced in Combination Chemotherapy Including Both Teniposide and Vincristine”, <i>Cancer Treat Rep.</i>, 1986, 70(4):519-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3009012\">[PubMed 3009012]</a></p>\n<p>5. Khan TS, Sundin A, Juhlin C, et al, “Vincristine, Cisplatin, Teniposide, and Cyclophosphamide Combination in the Treatment of Recurrent or Metastatic Adrenocortical Cancer,” <i>Med Oncol</i>, 2004, 21(2):167-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15299189\">[PubMed 15299189]</a></p>\n<p>6. Rivera G, Bowman WP, Murphy SB, et al, “VM-26 with Predisone and Vincristine for Treatment of Refractory Acute Lymphoblastic Leukemia,” <i>Med Pediatr Oncol</i>, 1982, 10(5):439-46. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6958957\">[PubMed 6958957]</a></p>\n<p>7. Owellen RJ, Hartke CA, Dickerson RM, et al, “Inhibition of Tubulin-Microtubule Polymerization by Drugs of the Vinca Alkaloid Class,” <i>Cancer Res</i>, 1976, 36(4):1499-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1260766\">[PubMed 1260766]</a></p>\n<p>8. Blanco JG, Harrison PL, Evans WE, et al, “Human Cytochrome P450 Maximal Activities in Pediatric Versus Adult Liver,” <i>Drug Metab Dispos</i>, 2000, 28(4):379-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10725303\">[PubMed 10725303]</a></p>\n<p>9. Egbelakin A, Ferguson MJ, Macgill EA, et al, “Increased Risk of Vincristine Neurotoxicity Associated with Low CYP3A5 Expression Genotype in Children with Acute Lymphoblastic Leukemia,” <i>Pediatr Blood Cancer</i>, 2011, 56(3): 361-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21072834\">[PubMed 21072834]</a></p>\n<p>10. Relling MV, Nemec J, Schuetz EG, et al, “O-demethylation of Epipodophyllotoxins is Catalyzed by Human Cytochrome P450 3A4,” <i>Mol Pharmacol</i>, 1994, 45(2): 352-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8114683\">[PubMed 8114683]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6974":"<p><b>Title</b> VinCRIStine / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin concentrations and decreased systemic effects of vincristine when these drugs are used in combination. Adjust phenytoin dose as needed based on results of serial concentration monitoring.</p> \n<p><b>Discussion</b> In a clinical study of 15 adults with brain tumors treated with vincristine (2 mg intravenously), procarbazine, and lomustine, vincristine AUC was 43% lower in 9 patients who were receiving phenytoin or carbamazepine compared to patients receiving neither drug.<sup>1</sup> The mechanism of this interaction has not been investigated, but likely involves induction of vincristine metabolism (e.g., via CYP3A4) by phenytoin or carbamazepine.<br><br>Vincristine prescribing information additionally states that coadministraiton of vincristine containing chemotherapy regimens with oral or intravenous phenytoin has been associated with decreased phenytoin concentrations and increased seizure activity.<sup>2</sup> One published case report describes a patient whose serum trough phenytoin concentration significantly and reproducibly declined during chemotherapy treatment cycles with vincristine, methotrexate, mercaptopurine, and prednisone (POMP-24).<sup>3</sup> During one treatment cycle, the patient's serum phenytoin concentration was maintained in the pre-chemotherapy range by approximately doubling the phenytoin dose. The mechanism of this interaction is unclear, and vincristine's role is uncertain due to the use of multiple additional medications.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Maenpaa H, et al, “Cytochrome P450-Inducing Antiepileptics Increase the Clearance of Vincristine in Patients With Brain Tumors,” <i>Clin Pharmacol Ther</i>, 1999, 66(6):589-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613614\">[PubMed 10613614]</a></p>\n<p>2. Prescribing information. Vincasar PFS (vincristine sulfate). Irvine, CA: Teva Parenteral Medicines, Inc., 12/2011.</p>\n<p>3. Jarosinski PF, Moscow JA, Alexander MS, et al, “Altered Phenytoin Clearance During Intensive Chemotherapy for Acute Lymphoblastic Leukemia,” <i>J Pediatr</i>, 1988, 112(6):996-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3163735\">[PubMed 3163735]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6975":"<p><b>Title</b> VinCRIStine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin concentrations and decreased systemic effects of vincristine when these drugs are used in combination. Adjust fosphenytoin dose as needed based on results of serial concentration monitoring.</p> \n<p><b>Discussion</b> In a clinical study of 15 adults with brain tumors treated with vincristine (2 mg intravenously), procarbazine, and lomustine, vincristine AUC was 43% lower in 9 patients who were receiving phenytoin or carbamazepine compared to patients receiving neither drug.<sup>1</sup> The mechanism of this interaction has not been investigated, but likely involves induction of vincristine metabolism (e.g., via CYP3A4) by phenytoin or carbamazepine.<br><br>Vincristine prescribing information additionally states that coadministraiton of vincristine containing chemotherapy regimens with oral or intravenous phenytoin has been associated with decreased phenytoin concentrations and increased seizure activity.<sup>2</sup> One published case report describes a patient whose serum trough phenytoin concentration significantly and reproducibly declined during chemotherapy treatment cycles with vincristine, methotrexate, mercaptopurine, and prednisone (POMP-24).<sup>3</sup> During one treatment cycle, the patient's serum phenytoin concentration was maintained in the pre-chemotherapy range by approximately doubling the phenytoin dose. The mechanism of this interaction is unclear, and vincristine's role is uncertain due to the use of multiple additional medications.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Maenpaa H, et al, “Cytochrome P450-Inducing Antiepileptics Increase the Clearance of Vincristine in Patients With Brain Tumors,” <i>Clin Pharmacol Ther</i>, 1999, 66(6):589-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613614\">[PubMed 10613614]</a></p>\n<p>2. Prescribing information. Vincasar PFS (vincristine sulfate). Irvine, CA: Teva Parenteral Medicines, Inc., 12/2011.</p>\n<p>3. Jarosinski PF, Moscow JA, Alexander MS, et al, “Altered Phenytoin Clearance During Intensive Chemotherapy for Acute Lymphoblastic Leukemia,” <i>J Pediatr</i>, 1988, 112(6):996-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3163735\">[PubMed 3163735]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6976":"<p><b>Title</b> VinCRIStine (Liposomal) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of liposomal vincristine in combination with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for liposomal vincristine states that concomitant treatment with any strong CYP3A inhibitor should be avoided.<sup>1</sup> Vincristine exposure could theoretically increase with coadministraiton of such inhibitors, although clinical data characterizing the potential magnitude of such interactions are not available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Marqibo (vincristine, liposomal). South San Francisco, CA: Talon Therapeutics, Inc., August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6977":"<p><b>Title</b> VinCRIStine (Liposomal) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of liposomal vincristine in combination with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 15 adults with brain tumors treated with non-liposomal vincristine (2 mg intravenously), procarbazine, and lomustine, vincristine AUC was 43% lower in 9 patients who were receiving phenytoin or carbamazepine compared to patients receiving neither drug.<sup>2</sup> The likely primary mechanism of this interaction is induction of hepatic metabolism of vincristine (e.g., via CYP3A4) by carbamazepine or phenytoin. Due to the potential for similar effects with liposomal vincristine, U.S. prescribing information for liposomal vincristine specifically states that concomitant treatment with any strong CYP3A inducer should be avoided.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. <i>Clin Pharmacol Ther</i>. 1999;66(6):589-593. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613614\">[PubMed 10613614]</a></p>\n<p>2. <i>Marqibo</i> (vincristine, liposomal) [prescribing information]. South San Francisco, CA: Talon Therapeutics Inc; August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6978":"<p><b>Title</b> VinCRIStine (Liposomal) / P-glycoprotein/ABCB1 Inducers</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of liposomal vincristine in combination with P-glycoprotein inducers.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin, St John's Wort</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for liposomal vincristine states that concomitant treatment with any potent P-glycoprotein (P-gp) inducer should be avoided.<sup>1</sup> P-gp transporters are widely expressed in the body, and induction of transporter expression and/or function could theoretically alter distribution (including distribution into target cells) or excretion (e.g., via increased renal or intestinal efflux) of vincristine. Specific clinical data characterizing the nature and potential magnitude of such interactions are not available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Marqibo (vincristine, liposomal). South San Francisco, CA: Talon Therapeutics, Inc., August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6979":"<p><b>Title</b> VinCRIStine (Liposomal) / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of liposomal vincristine in combination with P-glycoprotein inhibitors.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for liposomal vincristine states that concomitant treatment with any potent P-glycoprotein (P-gp) inhibitor should be avoided.<sup>1</sup> P-gp transporters are widely expressed in the body, and inhibition of transporter function could theoretically alter distribution (including distribution into target cells) or excretion (e.g., via decreased renal or intestinal efflux) of vincristine. Specific clinical data characterizing the nature and potential magnitude of such interactions are not available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Marqibo (vincristine, liposomal). South San Francisco, CA: Talon Therapeutics, Inc., August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6980":"<p><b>Title</b> Ceftibuten / Zinc Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction applies only to orally administered zinc salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zinc Salts may decrease the serum concentration of Ceftibuten. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider administering oral zinc salts at least 3 hours after ceftibuten.</p>\n<div>\n <p><b>Zinc Salts Interacting Members</b> Polaprezinc, Zinc Acetate, Zinc Gluconate, Zinc Sulfate<br><b>Exception</b> Zinc Chloride</p>\n</div> \n<p><b>Discussion</b> A study in rats found that concurrent administration of zinc with ceftibuten was associated with 50% inhibition of ceftibuten absorption, resulting in significant decreases in ceftibuten maximum concentration (Cmax) and prolonged time to maximum concentration (Tmax).<sup>1</sup> These results are consistent with the findings of an in vitro study where zinc was shown to inhibit the peptide transporter (PEPT1)-mediated uptake of the cephalosporins ceftibuten and cephradine in cultured cells.<sup>2</sup><br><br>Similarly, in a clinical study of 12 healthy volunteers, simultaneous coadministration of zinc sulfate (250 mg single oral dose) with the cephalosporin cephalexin (500 mg single oral dose), which is similarly dependent on PEPT1-mediated intestinal uptake, decreased cephalexin Cmax and AUC by 31% and 27%, respectively.<sup>3</sup> Cephalexin Cmax and AUC were decreased by 11% and 18%, respectively, when zinc sulfate was administered 3 hours before cephalexin, but there was no significant alteration of these variables when zinc sulfate was administered 3 hours after cephalexin.<br><br>This interaction appears to be at least partly attributable to zinc inhibition of PEPT1-mediated active uptake of ceftibuten from the gastrointestinal tract.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Okamura M, Terada T, Katsura T, et al, “Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide transporters in rats,” <i>Drug Metab Pharmacokinet</i>, 2008, 23(6):464-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19122341\">[PubMed 19122341]</a></p>\n<p>2. Okamura M, Terada T, Katsura T, et al, “Inhibitory Effect of Zinc on PEPT1-Mediated Transport of Glycylsarcosine and Beta-Lactam Antibiotics in Human Intestinal Cell Line Caco-2,” <i>Pharm Res</i>, 2003, 20(9):1389-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14567632\">[PubMed 14567632]</a></p>\n<p>3. Ding Y, Jia Y, Li F, et al, “The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin,” <i>Br J Clin Pharmacol</i>, 2012, 73(3):422-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023069\">[PubMed 22023069]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6981":"<p><b>Title</b> VinCRIStine (Liposomal) / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of liposomal vincristine in combination with St. John's wort.</p> \n<p><b>Discussion</b> In a clinical study of 15 adults with brain tumors treated with non-liposomal vincristine (2 mg intravenously), procarbazine, and lomustine, vincristine AUC was 43% lower in 9 patients who were receiving phenytoin or carbamazepine compared to patients receiving neither drug.<sup>1</sup> The likely primary mechanism of this interaction is induction of hepatic metabolism of vincristine (e.g., via CYP3A4) by carbamazepine or phenytoin. Due to the potential for similar effects with liposomal vincristine, U.S. prescribing information for liposomal vincristine specifically states that concomitant treatment with any strong CYP3A4 inducer should be avoided (St. John's wort is specifically listed as an example of a strong CYP3A4 inducer).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. <i>Clin Pharmacol Ther</i>. 1999;66(6):589-593. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613614\">[PubMed 10613614]</a></p>\n<p>2. <i>Marqibo</i> (vincristine, liposomal) [prescribing information]. South San Francisco, CA: Talon Therapeutics Inc; August 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6983":"<p><b>Title</b> Tiotropium / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of tiotropium with any other drugs that have anticholinergic properties. If such combinations can not be avoided, monitor patients closely for evidence of anticholinergic-related toxicities (e.g., urinary retention, constipation, tachycardia, dry mouth, etc.).</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Tiotropium prescribing information cautions that concurrent use of any other anticholinergic drugs should be avoided due to the risk for additive/excessive anticholinergic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Spiriva (tiotropium). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6984":"<p><b>Title</b> Raltegravir / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Raltegravir. Specifically, minimum serum concentrations (Cmin) may be reduced. Total raltegravir exposure (i.e., AUC) may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical response to raltegravir closely if used with rifabutin. Be particularly alert for evidence of reduced raltegravir effectiveness.</p> \n<p><b>Discussion</b> The average raltegravir minimum serum concentration (Cmin) was 20% lower, while the average raltegravir AUC was 19% higher when standard-dose raltegravir (400 mg twice/day) was used with rifabutin (300 mg/day).<sup>1</sup> This is in contrast to data with the related rifamycin rifampin, which has been associated with 40% and 61% average reductions in raltegravir AUC and Cmin, respectively, necessitating an increased raltegravir dose when used in combination.<sup>2,3</sup><br><br>Considering that the observed changes in raltegravir Cmin with rifabutin are less than those observed with the recommended high-dose raltegravir plus rifampin, it is unlikely that these changes are of clinical significance.<br><br>The suspected mechanism of this interaction is induction of raltegravir metabolism (via UGT1A1-mediated glucuronidation) by rifabutin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brainard DM, Kassahun K, Wenning LA, et al, “Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation,” <i>J Clin Pharmacol</i>, 2011, 51(6):943-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20852006\">[PubMed 20852006]</a></p>\n<p>2. Wenning LA, Hanley WD, Brainard DM, et al, “Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir,” <i>Antimicrob Agents Chemother</i>, 2009, 53(7):2852-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19433563\">[PubMed 19433563]</a></p>\n<p>3. Prescribing information. Isentress (raltegravir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 08/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6985":"<p><b>Title</b> Elvitegravir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifampin is contraindicated with elvitegravir/cobicistat/emtricitabine/tenofovir combination products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents. Similarly, use of single-agent elvitegravir with rifampin should be avoided.</p> \n<p><b>Discussion</b> Although specific data for elvitegravir plus rifampin are not available, elvitegravir AUC and minimum serum concentration (Cmin) were an average of 21% and 67% lower, respectively, when elvitegravir (150 mg/day) and cobicistat (150 mg/day) were given with rifabutin (150 mg every other day),<sup>1</sup> which is a rifamycin derivative that is a less potent inducer than rifampin. Given these findings, an even greater interaction would be expected with rifampin. Rifampin is contraindicated with elvitegravir/cobicistat/emtricitabine/tenofovir combination products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.<sup>1,2</sup> Similarly, US prescribing information for single-agent elvitegravir recommends avoiding concurrent use with rifampin.<sup>3</sup><br><br>The likely mechanism for this predicted interaction is rifampin induction of the CYP3A-mediated metabolism of elvitegravir. Rifampin may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of cobicistat, which is used in combination with elvitegravir in order to inhibit its metabolism and increase its serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6986":"<p><b>Title</b> Cobicistat / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of rifampin is contraindicated with cobicistat-containing products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance.</p> \n<p><b>Discussion</b> Although specific data for cobicistat with rifampin are not available, rifampin is contraindicated with cobicistat-containing products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance.<sup>1,2,3,4</sup><br><br>The likely mechanism for this predicted interaction is rifampin induction of the CYP3A-mediated metabolism of cobicistat, which is used to boost exposure to coadministered antiviral agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6987":"<p><b>Title</b> Dihydroergotamine / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Dihydroergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of dihydroergotamine is contraindicated with cobicistat-containing products due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of cobicistat with dihydroergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc).<sup>1,2,3,4</sup><br><br>This interaction is predicted based on the ability of cobicistat to inhibit CYP3A, which plays a significant role in the metabolism of dihydroergotamine.<sup>1,2,3,4,5</sup> Although specific data are not available, published case reports describe ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. <i>D.H.E. 45</i> (dihydroergotamine) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals North America; July 2002.</p>\n<p>6. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. <i>Postgrad Med J</i>. 1999;75(887):546-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>7. Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. <i>Antimicrob Agents Chemother</i>. 1997;41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6988":"<p><b>Title</b> Ergotamine / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Ergotamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of ergotamine is contraindicated with cobicistat-containing products due to the potential for ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of cobicistat with ergotamine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities, characterized by paresthesias, cyanosis, pain, etc).<sup>1,2,3,4</sup><br><br>This interaction is predicted based on the ability of cobicistat to inhibit CYP3A, which plays a significant role in the metabolism of ergotamine.<sup>1,2,3,4,5</sup> Although specific data are not available, published case reports describe ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. <i>Cafergot</i> (ergotamine and caffeine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; August 2007.</p>\n<p>6. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. <i>Postgrad Med J</i>. 1999;75(887):546-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>7. Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. <i>Antimicrob Agents Chemother</i>. 1997;41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6989":"<p><b>Title</b> Methylergonovine / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Methylergonovine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of methylergonovine is contraindicated with cobicistat-containing products due to the potential for serious ergot toxicity.</p> \n<p><b>Discussion</b> Concurrent use of cobicistat with methylergonovine is contraindicated due to the potential for significant ergot toxicity (excessive vasoconstriction in the extremities characterized by paresthesias, cyanosis, pain, etc).<sup>1</sup><br><br>This interaction is predicted based on the ability of cobicistat to inhibit CYP3A, which plays a significant role in the metabolism of methylergonovine.<sup>1,2</sup> Although specific data regarding this combination are not available, there are published case reports describing ergot toxicity in patients receiving ergotamine with the strong CYP3A inhibitor ritonavir.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. <i>Methergine</i> (methylergonovine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2012.</p>\n<p>6. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. <i>Postgrad Med J</i>. 1999;75(887):546-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616689\">[PubMed 10616689]</a></p>\n<p>7. Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. <i>Antimicrob Agents Chemother</i>. 1997;41(5):1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9145904\">[PubMed 9145904]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6990":"<p><b>Title</b> Cisapride / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of cisapride is contraindicated with cobicistat-containing products due to the potential for cisapride-related toxicities.</p> \n<p><b>Discussion</b> Concurrent use of cobicistat with cisapride is contraindicated due to the potential for significant cisapride toxicity.<sup>1,2,3,4</sup> This interaction is predicted based on the ability of cobicistat to inhibit CYP3A, which plays a significant role in the metabolism of cisapride.<sup>1,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. Pearce RE, Gotschall RR, Kearns GL, Leeder JS. Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. <i>Drug Metab Dispos</i>. 2001;29(12):1548-1554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11717173\">[PubMed 11717173]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6991":"<p><b>Title</b> Cobicistat / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Cobicistat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of St. John's wort is contraindicated with cobicistat-containing products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance.</p> \n<p><b>Discussion</b> Although specific data for cobicistat with St. John's wort are not available, St. John's wort is contraindicated with cobicistat-containing products due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance.<sup>1,2,3,4</sup><br><br>The likely mechanism for this predicted interaction is St John's wort induction of the CYP3A-mediated metabolism of cobicistat, which is used to boost systemic exposure of coadministered antiviral agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6992":"<p><b>Title</b> Elvitegravir / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of St Johns wort is contraindicated with elvitegravir/cobicistat/emtricitabine/tenofovir combination products, and is not recommended in combination with single-agent elvitegravir, due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance to these agents.</p> \n<p><b>Discussion</b> Although specific data for elvitegravir plus St Johns wort are not available, St Johns wort is contraindicated with elvitegravir/cobicistat/emtricitabine/tenofovir combination products, and is not recommended in combination with single-agent elvitegravir, due to the potential for decreased antiviral concentrations and effectiveness and the associated increased risk for viral resistance.<sup>1,2,3</sup><br><br>The likely mechanism for this predicted interaction is St Johns wort induction of the CYP3A-mediated metabolism of elvitegravir. St Johns wort may also enhance the glucuronidation of elvitegravir and may enhance the metabolism of coadministered cobicistat or ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6995":"<p><b>Title</b> Midazolam / Cobicistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: The severity of this interaction is likely to be notably greater with oral midazolam than with intravenous midazolam.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Midazolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of oral midazolam is contraindicated with cobicistat-containing products due to the potential for serious midazolam toxicity. Intravenous (IV) midazolam should be used with caution, in a setting equipped to appropriately monitor for and treat any excessive response to midazolam. Reduced doses of IV midazolam should be considered, particularly if multiple doses may be used.</p> \n<p><b>Discussion</b> Concurrent use of cobicistat with oral midazolam is contraindicated due to the potential for significant midazolam toxicity.<sup>1</sup> This interaction is predicted based on the ability of cobicistat to inhibit CYP3A, which plays a significant role in the metabolism of midazolam.<sup>1,2,3,4</sup> The magnitude of interaction with oral midazolam may be greater due to inhibition of CYP3A in both the intestine and liver, and the resultant decrease in first-pass metabolism of midazolam.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6996":"<p><b>Title</b> Elvitegravir / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Elvitegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an interaction. Consider the use of an H2-receptor antagonist or a proton pump inhibitor for patients who require more substantial and/or longer-term acid control, as these agents do not appear to interact with elvitegravir products.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> According to US prescribing information, in a series of studies (n=8-11) the average elvitegravir AUC and minimum serum concentrations (Cmin) were an average of 15-20% and 10-20% lower, respectively, when elvitegravir 50 mg and ritonavir 100 mg were given 2 hours before or 2 hours after a single dose (20 mL) of an antacid.<sup>1,2</sup> Conversely, when elvitegravir/ritonavir were given 4 hours before or 4 hours after an antacid dose (20 mL) the elvitegravir was minimally (i.e., less than 5%) and non-significantly changed.<br><br>The specific mechanism of this interaction is not certain, but considering that H2-receptor antagonists and proton pump inhibitors do not appear to have significant interactions with elvitegravir, the mechanism is more likely to involve direct chelating-type interactions with the antacids than pH changes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p>2. Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; November 2015.</p>\n<p>3. Vitekta (elvitegravir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; July 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6997":"<p><b>Title</b> Cobicistat / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Clarithromycin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to clarithromycin in patients receiving cobicistat-containing products. Monitor patients receiving these combinations for evidence of clarithromycin toxicity, including evidence of QT interval prolongation. Reduce clarithromycin dose by 50% in patients with an estimated creatinine clearance of 50 to 60 mL/min who are receiving elvitegravir/cobicistat/emtricitabine/tenofovir.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products states that concurrent use with clarithromycin may be associated with increased concentrations of cobicistat and/or clarithromycin.<sup>1,2,3,4</sup> Prescribing information for the elvitegravir/cobicistat/emtricitabine/tenofovir combination product recommends caution and increased monitoring in patients receiving this combination, and a 50% clarithromycin dose reduction for patients with an estimated creatinine clearance of 50 to 60 mL/min.<br><br>Cobicistat may inhibit CYP3A4 mediated metabolism of clarithromycin to its 14-hydroxy metabolite. Increased clarithromycin concentrations can increase the risk of drug-induced QT-prolongation and the development of life-threatening ventricular arrhythmias. Although specific data regarding this combination are not available, ritonavir (200 mg every 8 hours), a potent CYP3A4 inhibitor (as is cobicistat), increased the clarithromycin AUC by an average of 77% and almost completely inhibited formation of its active 14-hydroxy metabolite in a study of 22 healthy volunteers.<sup>5</sup> These effects on the 14-hydroxy active metabolite are of potentially clinically significant as this metabolite may account for a considerable portion of the total clarithromycin activity against <i>H. influenzae</i>.<sup>6,7</sup> Clarithromycin may similarly alter cobicistat concentrations by inhibiting its metabolism via CYP3A.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>5. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. <i>Clin Pharmacol Ther</i>. 1998;64(4):355-362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9797791\">[PubMed 9797791]</a></p>\n<p>6. Hardy DJ, Swanson RN, Rode RA, March K, Shipkowitz NL, Clement JJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. <i>Antimicrob Agents Chemother</i>. 1990;34(7):1407-1413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2143642\">[PubMed 2143642]</a></p>\n<p>7. Vallee E, Azoulay-Dupuis E, Swanson R, Bergogne-Bérézin E, Pocidalo JJ. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. <i>J Antimicrob Chemother</i>. 1991;27(suppl A):31-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827100\">[PubMed 1827100]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6998":"<p><b>Title</b> Telithromycin / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Telithromycin may increase the serum concentration of Cobicistat. Cobicistat may increase the serum concentration of Telithromycin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider alternatives to telithromycin in patients receiving cobicistat-containing products. Monitor patients receiving this combination for evidence of telithromycin toxicity, including evidence of QT interval prolongation. US prescribing information for the combination product containing elvitegravir, cobicistat, emtricitabine, and tenofovir does not address this potential interaction.</p> \n<p><b>Discussion</b> US prescribing information for several cobicistat-containing products recommends that alternatives to concomitant telithromycin be sought due to the potential for elevated exposure to telithromycin and/or cobicistat with combined use.<sup>1,2,3</sup> Prescribing information for the combination product containing elvitegravir, cobicistat, emtricitabine, and tenofovir does not address this potential interaction..<sup>4</sup><br><br>The mechanism of this potential interaction is unclear. Because cobicistat and telithromycin are inhibitors and substrates of CYP3A, each may inhibit the other drug's metabolism, leading to increased concentrations and the possibility of increased toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>3. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6999":"<p><b>Title</b> Warfarin / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Increase monitoring for evidence of excessive warfarin effects (eg, signs/symptoms of bleeding, increased INR) when this combination is used.</p> \n<p><b>Discussion</b> US prescribing information for cobicistat-containing products states that concurrent use with warfarin warrants INR monitoring due to unknown effects of cobicistat on warfarin exposure and effects.<sup>1,2,3,4</sup> The potential mechanism of interaction between these agents is unclear. Cobicistat is a strong inhibitor CYP3A, which is partly responsible for the metabolism of R-warfarin, suggesting that cobicistat may increase the concentration and effects of warfarin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}